ZacharyDavidCreesMD

Resident, PGY4

Dr. Crees is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Washington University/B-JH/SLCH ConsortiumChief Residency, Internal Medicine, 2018 - 2019
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 2015 - 2018
University of Illinois College of MedicineClass of 2015

PubMed

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi
Journal of the National Comprehensive Cancer Network. 2024-11-01
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma.
Scott R Goldsmith, Michael J Slade, Mark Fiala, Melinda Harding, Zachary D Crees
Annals of Hematology. 2024-11-01
Clinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report.
Bahareh A Mojarad, Zachary D Crees, Molly C Schroeder, Zhifu Xiang, Justin Vader
Cancer Genetics. 2024-01-01

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024November 5th, 2024
BioLineRx Presents Data from Pivotal GENESIS Trial of Motixafortide plus G-CSF for Stem Cell Mobilization in Multiple Myeloma Patients; NDA Submission Planned in 2022December 17th, 2021
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 17th, 2021